{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T01:57:10Z","timestamp":1770688630915,"version":"3.49.0"},"reference-count":52,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2023,8,6]],"date-time":"2023-08-06T00:00:00Z","timestamp":1691280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>Intravenous tocilizumab (TCZ\u2010IV) was approved for the treatment of adult Still's disease (ASD) in Japan in May 2019 based on its efficacy and safety in a phase III randomized controlled trial. This study determined treatment patterns in patients with ASD and assessed oral glucocorticoid (GC) dose changes after TCZ\u2010IV administration in Japanese clinical practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients in the Medical Data Vision database aged 16\u2009years or older with one or more of International Classification of Diseases, 10th revision codes M061 (ASD) or M082 (systemic juvenile idiopathic arthritis) during January 2017\u2013March 2021 (cohort 1) and those initiating TCZ\u2010IV during May 2019\u2013March 2021 (cohort 2) were included.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In cohort 1, the proportion of patients who were prescribed interleukin\u20106 inhibitors (mainly TCZ\u2010IV) increased from 10.8% (January\u2013April 2019 [before TCZ\u2010IV approval]; <jats:italic>n<\/jats:italic>\u2009=\u20092002) to 18.3% (January\u2013March 2021 [after TCZ\u2010IV approval]; <jats:italic>n<\/jats:italic>\u2009=\u20092008). In cohort 2 (<jats:italic>n<\/jats:italic>\u2009=\u2009193), 84.5% of patients were on oral GCs (\u22645\u2009mg\/day: 23.8%) at index date (initial TCZ\u2010IV prescription date); 46\/70 (65.7%) were on oral GC at 5\u2009mg\/day or higher 12\u2009months after TCZ\u2010IV treatment (primary outcome). After 12\u2009months of treatment, the TCZ\u2010IV retention rate was 73.6% and the TCZ\u2010IV administration interval was every 4\u2009weeks and every 2\u2009weeks in 31.9% and 27.7% of patients, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The use of interleukin\u20106 inhibitors increased by 7.5% points in Japanese patients with ASD ~2\u2009years after TCZ\u2010IV approval, suggesting that an unmet medical need existed. This study suggests the potential GC\u2010sparing effect of TCZ\u2010IV in patients with ASD in clinical practice.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1756-185x.14848","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T06:47:22Z","timestamp":1691390842000},"page":"1967-1978","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Treatment pattern and changes in oral glucocorticoid dose after tocilizumab treatment in patients with adult Still's disease: An analysis of a Japanese claims database"],"prefix":"10.1111","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2646-5765","authenticated-orcid":false,"given":"Yuko","family":"Kaneko","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine Keio University School of Medicine  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4330-5782","authenticated-orcid":false,"given":"Hideto","family":"Kameda","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine Toho University Ohashi Medical Center  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0574-9611","authenticated-orcid":false,"given":"Kei","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology Chiba University Hospital  Chiba Japan"},{"name":"Department of Rheumatology Dokkyo Medical University  Tochigi Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhisa","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd.  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1142-4162","authenticated-orcid":false,"given":"Ryoto","family":"Ozaki","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd.  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine University of Occupational and Environmental Health  Kitakyushu Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,8,6]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1942832"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0081-x"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-014-8561-9"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-015-0047-3"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2018.1465633"},{"key":"e_1_2_11_7_1","first-page":"33","article-title":"Treatment of adult\u2010onset Still's disease: a review","volume":"11","author":"Jamilloux Y","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1839411"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-016-1435-y"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27532"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.06.004"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-011-0569-6"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2017.1375853"},{"issue":"11","key":"e_1_2_11_14_1","first-page":"2422","article-title":"Serum cytokine profiles in patients with adult onset Still's disease","volume":"30","author":"Choi JH","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.01.058"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2014.971052"},{"issue":"11","key":"e_1_2_11_17_1","first-page":"2189","article-title":"Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease","volume":"31","author":"Chen DY","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1590334"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213920"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roab004"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2014.973659"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20319"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-013-2381-5"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13936"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-020-04622-4"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60454-7"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112802"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202310"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61223-3"},{"key":"e_1_2_11_30_1","unstructured":"Japanese Law Translation.Act on Medical Care for Patients with Intractable Diseases. Cited May 25 2023."},{"key":"e_1_2_11_31_1","unstructured":"MDV Database.cited May 19 2022.https:\/\/en.mdv.co.jp\/about\u2010mdv\u2010database\/"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq433"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-009-1097-z"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.54.4935"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2014.899178"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-016-3546-8"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2014.974881"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02708-3"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-019-04358-w"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1652591"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1838-6"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.09.014"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-022-02780-3"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.7326\/M20-1594"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016682"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-13639-y"},{"issue":"6","key":"e_1_2_11_47_1","first-page":"S64","article-title":"Efficacy of tocilizumab therapy in Korean patients with adult\u2010onset Still's disease: a multicentre retrospective study of 22 cases","volume":"34","author":"Song ST","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2014.992949"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38398"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05921-2"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130881"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2017.1416924"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1080\/24725625.2020.1818961"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.14848","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T23:57:14Z","timestamp":1697068634000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.14848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,6]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1111\/1756-185X.14848"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.14848","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,6]]},"assertion":[{"value":"2023-01-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}